Browsing Tag
Akeso Inc.
6 posts
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.
Akeso secures fifth NMPA breakthrough therapy designation for ivonescimab, sharpening its first-line oncology ambitions in China
Akeso Inc. secures a fifth breakthrough therapy designation for ivonescimab. Find out why this matters for oncology strategy and investors.
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after positive Phase III trial
Akeso files gumokimab for NMPA review in ankylosing spondylitis. Find out how this move expands its autoimmune pipeline beyond oncology.
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!
Akeso launches global Phase II trial of cadonilimab for IO-resistant liver cancer patients
Akeso begins a global Phase II trial of cadonilimab in advanced liver cancer. Find out how this bispecific IO drug could reshape second-line HCC therapy.
Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the…